CurcumaSorb provides the patented Meriva® curcumin-phosphatidylcholine complex for enhanced absorption and bioavailability.

The proprietary phytosome technology combines curcumin and phosphatidylcholine in a 1:2 ratio, promoting resistance to degradation in the digestive tract and efficient absorption across membranes. This produces significantly higher peak plasma concentrations and larger area under concentration-time curves (AUC).

In a single-dose pharmacokinetic animal study, plasma curcumin levels were 20 times greater with Meriva® than standard curcumin.

A preliminary human pharmacokinetic study demonstrated that elevations in plasma curcumin from 450 mg Meriva® were similar to values obtained from 4,000 mg of a standard curcumin extract.

The efficacy of a low dose was demonstrated in a three-month clinical trial, in which 200 mg curcuminoids from Meriva® per day helped relieve joint inflammation and provided significant benefit in joint comfort, mobility and quality of life when used in conjunction with conventional treatment.